This is the authors' abstract. We don't add key points for this paper.
Primary Coenzyme Q (CoQ) deficiency caused by COQ4 defects is a clinically heterogeneous mitochondrial condition characterized by reduced levels of CoQ 10 in tissues. Next-generation sequencing has lately boosted the genetic diagnosis of an increasing number of patients. Still, functional validation of new variants of uncertain significance is essential for an adequate diagnosis, proper clinical management, treatment, and genetic counseling. Both fibroblasts from a proband with COQ4 deficiency and a COQ4 knockout cell model have been characterized by a combination of biochemical and genetic analysis (HPLC lipid analysis, Oxygen consumption, minigene analysis, RNAseq, among others). Here, we report the case of a subject harboring a new variant of the COQ4 gene in compound heterozygosis, which shows severe clinical manifestations. We present the molecular characterization of this new pathogenic variant affecting the splicing of COQ4 . Our results highlight the importance of expanding the genetic analysis beyond the coding sequence to reduce the misdiagnosis of primary CoQ deficiency patients. • Defects in COQ4 cause the accumulation of the 3-decaprenyl-4-hydroxybenzoate. • The combination of COQ4 c.532 + 6 T > A and c.23_33del variants is disease-causing. • The combination of these variants causes defects in CoQ biosynthesis. • These variants cause a reduced ability to respond to increased energetic demand. • The COQ4 variant c.532 + 6 T > A is spliceogenic.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Alcázar‐Fabra et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: